Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Suresnes
Clinical trial register · France

Clinical Trials in Suresnes, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9726 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:21 UTC
9726
Studies in scope
all four open statuses
6052
Recruiting now
open to new participants
1030
Lead sponsors
across recruiting studies
Top sites
Paris 2846 Lyon 1398 Bordeaux 1393 Marseille 1291 Lille 1276

Trials with a site in Suresnes

98 of 9726 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Not yet open
Endoscopic Treatment
NCT07727824Stenoses, Dyspnea
University Hospital, Toulouse
Not applicable
96
Le Plessis-Robinson, Lille, Limoges, Strasbourg, Suresnes, Toulouse
2027-01
Not yet open
Assistance Publique - Hôpitaux de Paris
Phase 3
254
Aurillac, Bron, Marseille, Bayeux, Caen, Suresnes, Rennes, Angers
2026-12
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1/2
400
Marseille, Montpellier, Paris, Rennes, Saint-Herblain, Suresnes, Vandœuvre-lès-Nancy, Villejuif
2026-10-13
Not yet open
Assessment of Information Provided on Infectious Risk in Solid Organ Transplantation
NCT07788417Transplantation Infection, Pulmonary Transplantation
Fondation Hôpital Saint-Joseph
Observational
1,000
Paris, Bordeaux, Lyon, Marseille, Nantes, Strasbourg, Suresnes
2026-09-15
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
AstraZeneca
Phase 3
230
Bron, Marseille, Montpellier, Nantes, Paris, Pessac, Suresnes
2026-07-24
Not yet open
University Hospital, Rouen
Not applicable
350
Amiens, Lille, Rouen, Suresnes
2026-07-01
Not yet open
Hopital Foch
Not applicable
450
Garches, Paris, Suresnes
2026-06-30
Recruiting
Hopital Foch
Phase 2
36
Besançon, Bordeaux, Caen, Lille, Paris, Suresnes
2026-06-24
Not yet open
Hopital Foch
Not applicable
50
Suresnes
2026-06
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
Nice, Paris, Suresnes
2026-03-31
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Cedex Lyon 08, Grenoble, Lille, Marseille, Paris, Rennes, Strasbourg, Suresnes
2026-03-12
Recruiting
SCENAR Therapy in Chronic Non-specific Neck Pain
NCT07742228Cervicalgia, Neck Pain, Chronic Pain
Hopital Foch
Not applicable
76
Suresnes
2026-03-11
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Pessac, Besançon, Toulouse, Rouen, Suresnes, Saint-Herblain, Lorient, Lille
2025-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Bordeaux, Suresnes, Montpellier, La Tronche, Nancy, Angers, Bayonne, Pierre-Bénite
2025-11-26
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
162
Dijon, Grenoble, Paris, Suresnes, Toulon, Villejuif
2025-11-17
Not yet open
Fondation Hôpital Saint-Joseph
Not applicable
2,052
Boussy-Saint-Antoine, Lyon, Nantes, Paris, Saint-Cloud, Saint-Etienne, Suresnes, Toulouse
2025-11
Recruiting
AstraZeneca
Phase 1/2
283
Lyon, Montpellier, Saint-Herblain, Suresnes, Villejuif
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Nice, Strasbourg, Bordeaux, Lyon Cedex08, Brest, Suresnes, Saint-Herblain, Marseille
2025-09-30
Recruiting
Sanofi
Phase 3
124
Clichy, Dijon, Lille, Lyon, Marseille, Pessac, Suresnes
2025-09-26
Recruiting
Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months
NCT06723717Ruptured Aneurysm of Intracranial Artery, SAH (Subarachnoid Hemorrhage), Delayed Cerebral Ischemia
Fondation Ophtalmologique Adolphe de Rothschild
Phase 2
304
Grenoble, Lyon, Montpellier, Poitiers, Strasbourg, Suresnes
2025-09-26
Not yet open
Assistance Publique - Hôpitaux de Paris
Not applicable
346
Lille, Marseille, Paris, Rouen, Suresnes, Villejuif
2025-09
Recruiting
AstraZeneca
Phase 2
278
Avignon, Paris, Rennes, Saint-Herblain, Suresnes
2025-08-07
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Nice, Marseille, Quint-Fonsegrives, Suresnes
2025-07-07
Active, closed
Prediction of Lung Transplant Outcome
NCT07356752Graft Dysfunction, Lung Transplantation, Chronic Lung Allograft Dysfunction (CLAD), Chronic Rejection of Lung Transplant
Hopital Foch
Not applicable
4,200
Paris, Strasbourg, Talence, Grenoble, Le Plessis-Robinson, Lyon, Nantes, Suresnes
2025-06-17
Not yet open
Pilot Study of PEnile TRAnsplantation - Vascularized Composite Allografts
NCT06781606Adults with Traumatic Penile Severe Defects, Congenital Penile Defects, Micropenis
Hospices Civils de Lyon
Not applicable
3
Bordeaux, Lille, Lyon, Marseille, Montpellier, Pierre-Bénite, Suresnes, Toulouse
2025-06-01
Not yet open
Hopital Foch
Not applicable
60
Suresnes
2025-05-31
Active, closed
UroMems SAS
Not applicable
140
Lille, Marseille, Nantes, Paris, Pierre-Bénite, Rennes, Rouen, Suresnes
2025-05-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Suresnes, Strasbourg, Marseille, Caen, Besançon, Nîmes, Limoges, Vandœuvre-lès-Nancy
2025-05-13
Recruiting
Biogen
Phase 3
454
Strasbourg, Besançon, Bordeaux, Reims, Mulhouse, Suresnes, Orléans, Nîmes Cédex 9
2025-05-08
Recruiting
BioNTech SE
Phase 1/2
594
Créteil, Marseille, Suresnes, Toulouse
2025-05-02
Recruiting
AstraZeneca
Phase 2
540
Brest, Créteil, Lyon, Marseille, Pessac, Strasbourg, Suresnes
2025-03-26
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
Dijon, Bordeaux, Rouen, Suresnes, Paris
2025-03-11
Active, closed
Amgen
Phase 2
252
Pierre-Bénite, Rennes, Suresnes
2025-02-26
Recruiting
Hopital Foch
Phase 2
35
Marseille, Nantes, Paris, Suresnes
2025-02-18
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Bordeaux, Dijon, Lille, Paris, Saint-Herblain, Suresnes, Toulouse, Villejuif
2025-01-29
Recruiting
AstraZeneca
Phase 3
1,160
Avignon, La Rochelle, Lyon, Nîmes, Rennes, Strasbourg, Suresnes, Toulon
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Avignon, La Rochelle, Lyon, Nîmes, Rennes, Strasbourg, Suresnes, Toulon
2024-11-18
Active, closed
Pfizer
Phase 3
609
Nice, Lyon Cedex08, Strasbourg, Brest, Nîmes, Toulouse, Lille, Suresnes
2024-10-21
Recruiting
Institut Curie
Not applicable
60
Antony, Paris, Saint-Cloud, Saint-Mandé, Suresnes
2024-10-14
Recruiting
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
NCT06370182Acute Ischemic Stroke From Large Vessel Occlusion
Anaconda Biomed S.L.
Not applicable
327
Montpellier, Paris, Suresnes, Toulouse
2024-09-09
Recruiting
EDAP TMS S.A.
Not applicable
100
Besançon, Bordeaux, Lille, Lyon, Martigues, Suresnes, Toulon, Toulouse
2024-08-23
Recruiting
Hopital Foch
Phase 3
120
Paris, Suresnes
2024-08-20
Recruiting
Hopital Foch
Not applicable
350
Suresnes
2024-08-02
Recruiting
Daiichi Sankyo
Phase 1/2
123
Lille, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Suresnes, Villejuif
2024-07-22
Recruiting
Hopital Foch
Phase 2
640
Suresnes, Bron, Marseille, Paris
2024-05-10
Recruiting
ANRS, Emerging Infectious Diseases
Phase 2
69
Bobigny, Clamart, Clichy, Créteil, Garches, Le Kremlin-Bicêtre, Paris, Suresnes
2024-04-11
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Lille, Limoges, Marseille, Paris, Quint-Fonsegrives, Rennes, Suresnes
2024-04-09
Recruiting
A Prospective Randomized Trial of ECP in Subclinical AMR
NCT06112951Antibody-mediated Rejection, Lung Transplant Rejection
Medical University of Vienna
Not applicable
80
Suresnes
2024-03-01
Recruiting
Veno-arterial ExtraCorporeal Membrane Oxygenation to Reduce Morbidity and Mortality Following Lung TransPlant
NCT05664204The Number of Ventilator-free Days in the 28 Days Following LT
Assistance Publique - Hôpitaux de Paris
Not applicable
200
Paris, Suresnes
2024-02-29
Active, closed
CarThera
Phase 3
560
Bron, Marseille, Paris, Suresnes
2024-01-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Bordeaux, Lyon Cedex08, Strasbourg, Brest, Quint-Fonsegrives, Lille, Suresnes, Clermont-Ferrand
2023-12-18
Recruiting
Hopital Foch
Not applicable
66
Suresnes
2023-12-14
Recruiting
FIH XON7 in Advanced/Metastatic Solid Tumors
NCT06154291Advanced Solid Tumor, Metastatic Cancer
Xenothera SAS
Phase 1/2
255
Bordeaux, Lyon, Suresnes, Toulouse
2023-11-14
Recruiting
Centre Hospitalier St Anne
Not applicable
450
Garches, Le Kremlin-Bicêtre, Paris, Suresnes
2023-10-16
Recruiting
Sanofi
Phase 3
180
Le Plessis-Robinson, Marseille, Paris, Pessac, Saint-Herblain, Strasbourg, Suresnes
2023-10-10
Recruiting
Institut Curie
Not applicable
50
Paris, Suresnes
2023-08-03
Active, closed
Swedish Orphan Biovitrum
Observational
165
Nice, Pessac, Suresnes, Grenoble, Nantes, Vandœuvre-lès-Nancy, Lille, La Defense
2023-06-26
Active, closed
Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation
NCT05701228Cytomegalovirus Infections, Solid Organ Transplantation
University Hospital, Bordeaux
Observational
552
Bordeaux, Lyon, Paris, Suresnes, Toulouse, Villejuif
2023-06-26
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Besançon, Bron, Essey-lès-Nancy, Lyon, Massy, Nîmes, Rouen, Suresnes
2023-04-25
Active, closed
AlgoTherapeutix
Phase 2
276
Bayonne, Bordeaux, Montpellier, Paris, Poitiers, Reims, Strasbourg, Suresnes
2023-02-28
Active, closed
Gilead Sciences
Phase 2
400
Bordeaux, Lyon, Strasboug, Suresnes
2023-02-21
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
DrugIP-001
Immunophotonics, Inc.
Phase 1/2
42
Bordeaux, Paris, Suresnes, Villejuif
2022-11-29
Active, closed
Mirati Therapeutics Inc.
Phase 2
90
Angers, Caen, Créteil, Dijon, La Tronche, Marseille, Paris, Suresnes
2022-11-22
Active, closed
Gilead Sciences
Phase 3
1,021
Boulogne-Billancourt, Le Mans, Marseille, Montpellier, Saint-Herblain, Saint-Mandé, Saint-Quentin, Suresnes
2022-10-12
Active, closed
Exelixis
Phase 3
901
Besançon, Dijon, Herbault, Lyon, Marseille, Paris, Suresnes
2022-09-07
Recruiting
AstraZeneca
Phase 2
454
Bordeaux, Lyon, Marseille, Suresnes
2022-09-06
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Suresnes, Angers, Bordeaux, Caen, Créteil, Le Mans, Lyon, Marseille
2022-08-17
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Bordeaux, Dijon, Marseille, Nantes, Paris, Poitiers, Saint-Herblain, Suresnes
2022-05-25
Recruiting
AstraZeneca
Phase 2
630
Avignon, Bobigny, Bordeaux, Limoges, Rennes, Rouen, Suresnes, Toulon
2022-04-14
Active, closed
Verastem, Inc.
Phase 1/2
153
Lille, Paris, Suresnes
2022-04-12
Recruiting
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
NCT04837339Lung Transplant Rejection, Lung Transplant Failure, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Hopital Foch
Not applicable
900
Suresnes
2022-03-17
Recruiting
Hopital Foch
Not applicable
72
Suresnes
2021-12-13
Active, closed
Sophia Genetics SAS
Observational
4,000
Bobigny, Bordeaux, Boulogne-Billancourt, Lyon, Nantes, Paris, Suresnes, Toulon
2021-08-21
Recruiting
Hopital Foch
Not applicable
14
Garches, Suresnes
2021-07-12
Active, closed
Bristol-Myers Squibb
Phase 3
681
Nice, Suresnes, Villejuif
2021-05-21
Recruiting
Gustave Roussy Cancer Profiling
NCT04932525Solid Tumor, Unspecified, Adult
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
20,000
Villejuif, Le Plessis-Robinson, Paris, Suresnes
2021-05-10
Recruiting
Hopital Foch
Phase 2/3
180
Suresnes
2021-03-18
Recruiting
Calico Life Sciences LLC
Phase 1
248
Marseille, Toulouse, Nice, Suresnes
2021-03-09
Recruiting
Hopital Foch
Not applicable
30
Suresnes
2020-09-21
Active, closed
AstraZeneca
Phase 3
134
Lille, Pessac, Strasbourg, Suresnes, Toulouse
2020-07-20
Recruiting
Institut Cancerologie de l'Ouest
Observational
300
Angers, La Roche-sur-Yon, Lyon, Montpellier, Nantes, Nice, Saint-Cloud, Suresnes
2020-07-10
Recruiting
Biomarkers and Choroidal Neovascularization
NCT04439708Choroidal Neovascularization, Mineralocorticoid Excess
Institut National de la Santé Et de la Recherche Médicale, France
Observational
250
Paris, Suresnes
2020-07-06
Active, closed
AstraZeneca
Phase 3
140
Dijon, Marseille, Montpellier, Nantes, Paris, Suresnes, Toulouse
2019-10-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Dijon, Rennes, Suresnes, Lille, Créteil
2018-12-24
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
Besançon, Bourgoin, Lyon, Marseille, Nantes, Pont-de-Vaux, Portes-lès-Valence, Suresnes
2018-06-25
Active, closed
AstraZeneca
Phase 3
1,018
Amiens, Angers, Bordeaux, Lyon, Marseille, Montpellier, Strasbourg, Suresnes
2018-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Suresnes, Pierre-Bénite, Strasbourg, Toulouse, Limoges, Chambéry, Pringy, Rouen
2018-04-24
Active, closed
Orion Corporation, Orion Pharma
Phase 1/2
204
Bordeaux, Lyon, Marseille, Strasbourg, Suresnes, Villejuif
2018-03-19
Recruiting
Hopital Foch
Not applicable
20
Suresnes
2017-12-14
Recruiting
Fondation Ophtalmologique Adolphe de Rothschild
Observational
1,200
Bordeaux, Caen, Limoges, Nancy, Nantes, Paris, Rennes, Suresnes
2017-07-13
Active, closed
Pfizer
Phase 3
296
Pessac, Chevilly-Larue, Le Mans, Marseille, Paris, Rennes, Suresnes, Toulouse
2017-04-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Clermont-Ferrand, Montpellier, Nancy, Paris, Pierre-Bénite, Strasbourg, Suresnes
2015-11-27
Active, closed
AstraZeneca
Phase 3
1,126
Bordeaux, Caen, Lyon, Marseille, Paris, Poitiers, Suresnes, Toulouse
2015-11-02
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Caen, Créteil, Lyon, Nantes, Paris, Poitiers, Saint-Herblain, Suresnes
2012-04-03
Rows per page Showing 1–98 of 98
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 November 2026. https://priyalifescience.com/clinical-trials-france/city/suresnes

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,726 studies in total at the last sync on 17 Nov 2026, 03:21 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 98 of those studies with a site in Suresnes.

How many clinical trials are recruiting in Suresnes?

55 of the 98 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:21 UTC sync. A further 10 have not yet opened recruitment, 33 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Suresnes), 98 studies
PhaseStudiesRecruitingShare
Phase 3271227.6%
Not applicable261626.5%
Phase 2211221.4%
Phase 1/211711.2%
Observational949.2%
Phase 2/3333.1%
Phase 1111%

Most active sponsors

Lead sponsors with the most studies (Suresnes)
Lead sponsorStudiesRecruiting
Hopital Foch1713
AstraZeneca128
Merck Sharp & Dohme LLC75
Bristol-Myers Squibb42
Assistance Publique - Hôpitaux de Paris31
Daiichi Sankyo22
EMD Serono Research & Development Institute, Inc.20
Fondation Hôpital Saint-Joseph20
Fondation Ophtalmologique Adolphe de Rothschild22
Gilead Sciences20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.